Volume 130, Issue 4, Pages 1054-1061 (April 2006) Infliximab Plus Azathioprine for Steroid-Dependent Crohn’s Disease Patients: A Randomized Placebo-Controlled Trial  Marc LÉmann, Jean–Yves Mary, Bernard Duclos, Michel Veyrac, Jean–Louis Dupas, Jean Charles Delchier, David Laharie, Jacques Moreau, Guillaume Cadiot, Laurence Picon, Arnaud Bourreille, Iradj Sobahni, Jean–Frederic Colombel  Gastroenterology  Volume 130, Issue 4, Pages 1054-1061 (April 2006) DOI: 10.1053/j.gastro.2006.02.014 Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 1 Flow chart of patients randomized in the trial. The figures in parentheses correspond to the number of patients in the naive stratum and the failure stratum, respectively. Gastroenterology 2006 130, 1054-1061DOI: (10.1053/j.gastro.2006.02.014) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 2 Percent of patients in clinical remission and off steroids at weeks 12, 24 (primary end point), and 52 (follow-up evaluation). The figures below the bars correspond to the number of patients analyzed at each date. □, AZA/6-MP + placebo; ■, AZA/6-MP + infliximab 5 mg/kg. Gastroenterology 2006 130, 1054-1061DOI: (10.1053/j.gastro.2006.02.014) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 3 Percent of patients in clinical remission and off steroids in the 2 strata at weeks 12, 24 (primary end point), and 52 (follow-up evaluation). The figures below the bars correspond to the number of patients analyzed at each date. □, AZA/6-MP + placebo; ■, AZA/6-MP + infliximab 5 mg/kg. Gastroenterology 2006 130, 1054-1061DOI: (10.1053/j.gastro.2006.02.014) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions